Preliminary Exploration of the Influence of Alcohol Consumption Levels on the Plasma Cell-free DNA Methylation Profiles in Subjects With Chronic Hepatitis B
Key facts
- Who runs it
- Beijing Municipal Administration of Hospitals
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 99 people enrolled
- Started
- 21 Nov 2025
- Ended
- 31 May 2026
- Type of study
- Observational, 3 groups
- Record updated
- 18 November 2026
Who can take part
- Age
- 30 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Age between 30 and 75 years old (inclusive of 30 but exclusive of 75)
- Diagnosis of chronic hepatitis B
- Signed informed consent form and willingness to comply with study sampling and evaluation procedures
Who cannot take part
- History of severe acute infectious diseases within 14 days before screening (e.g., severe or critical COVID-19 infection, sepsis)
- Use of the following medications within 14 days before screening: intravenous/oral glucocorticoids, intravenous/oral azacitidine, decitabine, procainamide, hydralazine, arsenic trioxide
- Prior organ, bone marrow or stem cell transplantation, or blood transfusion within 30 days before screening
- Personal history of malignancy, either prior to or at screening
- Any other condition deemed inappropriate for study participation by the investigator
- Diagnosis of liver cirrhosis
- Pregnant or lactating women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Existing studies have confirmed that there are differences in the methylation status of liver tissue due to hepatitis B virus infection and alcohol consumption. There are also differences in the methylation status at each stage of the disease progression from hepatitis to liver cirrhosis and then to liver cancer. However, no study has systematically compared the cfDNA methylation profiles of hepatitis B subjects under different alcohol consumption statuses. Plasma cfDNA methylation detection has been proven to be applicable for the early warning of HBV - related liver cancer and has the characteristics of being non - invasive and allowing dynamic monitoring. However, most of the existing markers focus on the "liver cancer transformation" stage, and there is a lack of typing markers suitable for the early stage of "hepatitis progression". To preliminarily explore this field, this project was initiated.
Read full original descriptionShow less
This study is an observational and exploratory study that does not involve clinical treatment intervention for the subjects. The project plans to enroll 85 subjects with chronic hepatitis B. They will be divided into a non - drinking group, a drinking group, and a group that has developed alcoholic hepatitis due to alcohol consumption according to the degree of alcohol consumption. For each patient, 2 tubes of peripheral blood (about 8 mL per tube), a total of about 16 mL, will be collected for cfDNA methylation analysis. By comparing the plasma cfDNA methylation profiles of chronic hepatitis B subjects with different degrees of alcohol consumption, the impact of different degrees of alcohol consumption on the cfDNA methylation of the subjects will be analyzed.
The 3 groups in the trial
- Non-drinking group
Drink less than twice a year, with no limit on the amount of alcohol consumed each time.
- Alcohol consumption group
An average of at least 50 g per day.
- Alcoholic hepatitis group
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- 慢性乙型肝炎受试者饮酒程度对血浆游离DNA甲基化图谱影响的初步探索
- Record updated
- 18 November 2026